ExodusPoint Capital Management LP Invests $16.75 Million in Immunome, Inc. $IMNM

Posted by Stanley Muller on Jun 17th, 2026

ExodusPoint Capital Management LP purchased a new stake in Immunome, Inc. (NASDAQ:IMNM – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 779,578 shares of the company’s stock, valued at approximately $16,745,000.

Other large investors have also added to or reduced their stakes in the company. Strs Ohio bought a new stake in Immunome in the fourth quarter valued at $64,000. Assetmark Inc. bought a new stake in Immunome in the third quarter valued at $39,000. Aster Capital Management DIFC Ltd bought a new stake in Immunome in the fourth quarter valued at $121,000. BIT Capital GmbH bought a new stake in Immunome in the third quarter valued at $69,000. Finally, BNP Paribas Financial Markets boosted its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Trading Down 0.9%

Shares of Immunome stock opened at $17.91 on Wednesday. The firm has a market capitalization of $2.03 billion, a P/E ratio of -7.53 and a beta of 2.04. The business has a fifty day simple moving average of $21.62 and a two-hundred day simple moving average of $21.70. Immunome, Inc. has a 12 month low of $7.96 and a 12 month high of $27.65.

Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. Analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Barclays assumed coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Craig Hallum lifted their price target on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a report on Friday, June 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Immunome in a report on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immunome currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Check Out Our Latest Report on Immunome

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 10,500 shares of the stock in a transaction on Friday, June 5th. The stock was acquired at an average price of $19.45 per share, with a total value of $204,225.00. Following the completion of the transaction, the director owned 43,415 shares of the company’s stock, valued at $844,421.75. This represents a 31.90% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total value of $753,296.00. Following the transaction, the director directly owned 369,347 shares of the company’s stock, valued at $7,560,533.09. This represents a 9.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

Immunome Profile

(Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.